Luigi Aurisicchio, CEO/CSO at Takis, has been invited to the event organized by Tecnopolo S.p.A and dedicated to Health Technology and Artificial Intelligence.
The meeting brings togheter companies and academic institutions involved in the study and experimentation of concrete technological solutions in medical field.
Dr. Aurisicchio will deliver a speech about Takis research in precision medicine, as we are developing a personalized cancer vaccine against tumor specific neoantigens (TK-NEO). This is a patient-tailored therapy with the potential to target metastatic and solid tumors, which we already validated in preclinical models.
Technological innovation has a great impact on health and medicine. This is where we make our contribution by implementing innovative individualized therapies based on the immune system against cancer and rare diseases.